We next explored whether the ability of metformin to reduce tumor-initiating capacity in BRCA1 one- hit cells correlated with a capacity to alter the highly anabolic (biosynthetic) signature driven by BRCA1 haploinsufficiency. Here, BRCA1 is linked to neoplasm.